Ratings AddLife AB

Equities

ALIF B

SE0014401378

Real-time Estimate Cboe Europe Other stock markets 11:25:00 2024-05-10 am EDT			5-day change	1st Jan Change
109.6 ^SEK	+2.05%		+6.27%	-0.91%

Apr. 24	Transcript : AddLife AB, Q1 2024 Earnings Call, Apr 24, 2024
Apr. 24	AddLife AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's profit outlook over the next few years is a strong asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company sustains low margins.
The company is in debt and has limited leeway for investment
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.43 times its estimated earnings per share for the ongoing year.
The company is not the most generous with respect to shareholders' compensation.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ADDLIFE AB	-2.29%	1.2B	C
MODERNA, INC.	+23.37%	47.02B	B-
LONZA GROUP AG	+50.01%	41.86B	A
IQVIA HOLDINGS INC.	-0.94%	41.76B	B
CELLTRION, INC.	-4.32%	28.8B	C
ICON PUBLIC LIMITED COMPANY	+11.29%	26.05B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.15B	B
BIO-TECHNE CORPORATION	+3.20%	12.55B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B	C+
MEDPACE HOLDINGS, INC.	+30.23%	12.34B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes